Senzime AB (publ) (SNZZF) Q1 2026 Earnings Call Prepared Remarks Transcript

Senzime reported a temporary Q1 2026 growth dip, with U.S. reported sales down 5% due to delayed TetraGraph deals and FX pressure from a stronger Swedish krona and weaker U.S. dollar. Offset by 40% constant-currency sensor sales growth, improving gross margin, and good operating cash flow, management said full-year targets remain intact. The main issue appears to be timing-related rather than a structural demand problem.

Analysis

The important read-through is not the headline growth wobble, but that the business is showing operating leverage exactly where scale matters: consumables and gross margin, while the hardware cycle is lumpy. That usually signals a platform crossing from installation-led revenue to recurring pull-through, which is higher quality than the market may be pricing after one weak U.S. quarter. If management is right that deals slipped rather than disappeared, the Q2/Q3 setup is asymmetric because delayed monitor placements should mechanically lift future sensor demand with little incremental selling cost.

The FX mix is masking underlying dollar momentum and creating a false signal for U.S. investors. A stronger SEK/softer USD can temporarily compress reported growth and obscure the health of local demand, but it does not change installed-base economics; in fact, it can force the market to miss the inflection until a later quarter when the currency lap gets easier. The second-order beneficiary of any delayed purchasing is likely the company itself, because a monitor installation deferred into one quarter often becomes a multi-quarter consumables annuity once the cabinet is in place.

The key risk is that this is not just timing but procurement friction tied to hospital capex scrutiny in the U.S. If that is the real issue, the rebound could take months, not weeks, and the market may keep de-rating the stock on each "delay" until management proves conversion. The consensus appears to be underestimating how quickly U.S. macro caution can hit small medtech hardware orders, but also underestimating how quickly margin and cash flow can re-rate the equity once growth re-accelerates on an easier compare.

Contrarian view: the quarter may be a better signal for near-term trading than for long-term fundamentals. Weak reported sales with improving gross margin and cash generation often marks the point where growth investors capitulate before the operating model inflects back up; if the next 1-2 prints show sequential monitor recovery, the stock can move sharply on a lower base. The market should focus less on reported top-line volatility and more on whether sensor growth remains strong enough to validate the installed-base thesis.

Key Decisions for Investors

• Long SNZZF on weakness for a 1-3 month trade: use the post-earnings dip to build a starter position, targeting a rebound if delayed U.S. monitor deals convert in Q2; risk/reward is attractive if the market is discounting timing rather than demand destruction.
• Add only on confirmation: buy a second tranche after evidence of sequential U.S. order recovery or sensor acceleration next quarter; this reduces the risk of catching a value trap if procurement slippage persists.
• Sell covered calls against any long SNZZF position into the next bounce: the stock likely has near-term upside capped until management proves the U.S. conversion, while premium can monetize the reporting gap.
• Pair trade idea: long SNZZF / short a U.S. capex-sensitive medtech hardware name with weaker consumables mix over the next 1-2 quarters; the thesis is recurring pull-through and margin resilience outperforming pure installation-led models.
• Set a risk trigger: if U.S. reported growth remains negative for another quarter despite strong sensor growth, exit the trade; that would shift the story from timing issue to demand elasticity problem.